Immunotherapy of T-ALL: Opportunities and hurdles

Bookmark and Share
Published: 10 Nov 2021
Views: 246
Dr Maksim Mamonkin - Baylor College of Medicine, Houston, USA

Dr Maksim Mamonkin talks to ecancer following his ALL Assembly talk.

He begins by talking about how cellular immunotherapy for T-ALL has been lagging behind similar approaches to B-Cell malignancies, largely because the antigens that are targetable in T-cell ALL are also expressed in normal T-cells, including CAR T-cells.

Dr Mamonkin then goes on to list 3 problems that need to be solved for the therapies to be safe and effective, including cell fratricide. He also mentions the development of a CD5 specific CAR where the expression on T-cells, surprising, leads to resistance of fratricide, as T-cells down regulate and degrade CD5 protein very efficiently, meaning they essentially become invisible to each other, evading fratricide.

He concludes by saying that right now we live in a very exciting time where we can now start offering patients with refractory relapsed T-ALL some immuno-engineered cell therapies that can offer much needed clinical solutions.


ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.